Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. (trading symbol: AADI) on June 30, 2022, reporting an event that occurred on June 27, 2022. The company is an emerging growth company incorporated in Delaware, focused on the development and commercialization of FYARRO (nab-sirolimus).
Key Financial Metrics and Agreement Details
The filing details the financial terms of a terminated license agreement with EOC Pharma (Hong Kong) Limited ("EOC") regarding the Greater China territory:
- Upfront Payment Received: $14.0 million (received January 2021).
- Milestone Payment Received: $1.0 million (received November 2021 upon FDA approval).
- Future Milestone Obligations (Terminated): Up to $257.0 million in potential non-refundable payments.
- Future Royalties (Terminated): Royalties on net sales in the EOC Territory.
The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
On June 27, 2022, EOC notified Aadi Bioscience of its election to terminate the License Agreement dated December 8, 2020, effective immediately. This action follows a notice delivered by EOC on April 14, 2022, alleging material breaches by the Company. The Company disputes these allegations and contends the termination is for convenience rather than for cause. Consequently, the Company has lost the exclusive rights granted to EOC to develop and commercialize FYARRO in Greater China, including the potential for future milestone payments and royalties.
Outlook, Risks, and Management Commentary
Management Commentary: The Company explicitly states it disagrees with EOC's allegations of material breach and does not believe EOC had the right to terminate the agreement for such reasons. The Company characterizes the event as a termination for convenience.
Risks and Contingencies: The termination eliminates a significant potential revenue stream (up to $257 million in milestones and royalties) for the Greater China market. The dispute over the nature of the termination (breach vs. convenience) may lead to further legal or financial contingencies not detailed in this summary.
Key Facts for Investor Verification
- Verify the Company's legal strategy regarding the dispute over the termination cause (breach vs. convenience).
- Confirm the impact of the lost Greater China territory on the Company's long-term revenue projections for FYARRO.
- Review subsequent filings for any litigation updates or financial restatements related to the $15 million already received under the agreement.
- Assess the Company's plan to re-license or self-develop FYARRO in the Greater China region.